TB Alliance seeks to support the accelerated development, registration, and launch of sutezolid for use as part of a universal regimen to treat drug-sensitive as well as drug-resistant tuberculosis (TB). As a result, we provide data generated by TB Alliance during its development of sutezolid as well as any drug substance and/or drug product (“sutezolid drug material”) to any investigator who is interested in conducting TB research with the compound and who agrees to meet all of the conditions described herein. The Sutezolid Independent Review Committee (SIRC) has been established by TB Alliance to review and approve all submitted proposals. The charter for the SIRC can be accessed here:
Please find the following agreements in connection with the SIRC agreeing to provide sutezolid data or sutezolid drug material:
- Data Transfer Agreement
- MTA for non-combination pre-clinical research
- MTA for combination pre-clinical research
- MTA for clinical research.
If you would like to submit a proposal, please access the application for here:
Members of the SIRC Committee
- Eugene Sun, TB Alliance
- Eric Nuermberger, Johns Hopkins Institute
- Wim Vandevelde, Advocate
- Dave Hermann, The Bill and Melinda Gates Foundation
- Jan Gheuens, Independent Senior Consultant
- Manuele Piccolis, Medicines Patent Pool
- Elisa Ignatius, Johns Hopkins Medicine International
- Almari Conradie, TB Alliance, SIRC Coordinator